Seminars in Hematology
Volume 45, Supplement 2 , Pages S11-S16, July 2008

Targeted Treatment and New Agents in Diffuse Large B-Cell Lymphoma

Center for Lymphoma and Myeloma and Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 STATEMENT OF CONFLICT OF INTEREST: John P. Leonard, Research support/Principal Investigator: Biogen Idec, Cephalon, Genentech, GSK, Immunetics, Millennium, Seattle Genetics; Consultant/Scientific Advisory Board: Berlex, Biogen Idec, Bristol Myers, Cougar Biotechnology, Genentech, GSK, Millennium, Wyeth; Speaker's Bureau: Biogen Idec, Genentech, GSK, Millennium.

PII: S0037-1963(08)00120-0

doi:10.1053/j.seminhematol.2008.07.004

Seminars in Hematology
Volume 45, Supplement 2 , Pages S11-S16, July 2008

Article Tools

* Image Usage & Resolution